Essential Partners’s Tvardi Therapeutics TVRD Stock Holding History

Essential Partners’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-60	Closed	-$191	–	2983
2026 Q1	$191	Buy	+60	New	+$235	﹤0.01%	2619

Other funds holding TVRD

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AFG

American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Essential Partners's TVRD Position: Q2 2026 in Review

Essential Partners sold out of Tvardi Therapeutics (TVRD) in Q2 2026, closing a stake of 60 shares — an estimated $191 sold.

Essential Partners first reported a position in TVRD in Q1 2026 and held it in 1 quarter. The position peaked at $191 in Q1 2026. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

Essential Partners reported no remaining Tvardi Therapeutics position as of Q2 2026 after selling out during the quarter.
Essential Partners sold 60 Tvardi Therapeutics shares in Q2 2026, an estimated $191.
Essential Partners first reported a position in Tvardi Therapeutics in Q1 2026 and held it in 1 quarter.
Essential Partners's Tvardi Therapeutics position peaked at $191 in Q1 2026.
58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.